Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.
“The PRO data presented here complements the published clinical efficacy and safety data, add the patient's voice, and support the use of EV/pembro for patients with locally advanced/metastatic urothelial cancer," says Shilpa Gupta, MD.
Updated findings from cohort H of the EV-103 study showed promising 2-year event-free survival outcomes and favorable antitumor activity with enfortumab vedotin in cisplatin-ineligible patients with muscle-invasive bladder cancer.
A post-hoc analysis of the phase 3 ARAMIS trial provided additional efficacy evidence for darolutamide in nmCRPC, including benefits related to prostate cancer–specific survival and reaching a PSA level <0.2 ng/mL.
Patients with advanced renal cell carcinoma treated with TKIs in the second or third line following lenvatinib treatment showed modest activity, highlighting the need for improved treatment options.
A retrospective cohort of patients with metastatic urothelial cancer who received prior enfortumab vedotin had low efficacy when treated with sacituzumab govitecan, with the best outcomes coming from directly sequencing the 2 agents.
“For patients who received darolutamide plus ADT and docetaxel, minimal differences in post-progression survival were observed between first subsequent therapies," said Marc-Oliver Grimm, MD.
In the EMBARK trial in patients with nonmetastatic hormone-sensitive prostate cancer, patients with good PSA responses at 37 weeks had their treatment suspended until their PSA started to rise again.
Adding cabazitaxel to abiraterone acetate and prednisone significantly reduced the risk of disease progression or death in patients with mCRPC previously treated with ADT plus docetaxel for HSPC.
This monotherapy was safe for all doses and dosing schedules observed in the study and daily doses showed initial antitumor activity.
Neoadjuvant therapy with sacituzumab govitecan demonstrated hypothesis generating complete responses following surgery with tolerable toxicity after a protocol amendment requiring a dose reduction and G-CSF prophylaxis for patients with muscle-invasive bladder cancer.
"In the cisplatin-ineligible cohorts, we showed that high event-free survival and overall survival rates can be achieved at 12 and 36 months in patients treated with neoadjuvant avelumab in combination with cisplatin-based chemotherapy," says Jeremy Blanc, MD.
Gilead reported that a numerical improvement in OS favoring sacituzumab govitecan was observed, though the end point was not reached in the intent-to-treat population.
"Although the Medicare physician fee schedule, which is typically the primary focus of many of our discussions, is what is used to determine physician payment for a service, payment for an ASC is governed by separate rules," write Jonathan Rubenstein, MD, and Mark Painter.
The request comes amid growing concerns about the rule’s implications for businesses and employees nationwide.
Patients with high-risk disease were shown to have a significantly higher mean value of SUVmax compared with patients with low-risk disease (23.5 ± 13.2 vs 10.6 ± 5.4; P < 0.05).
"There’s potentially a role here for patients with small renal masses that may not want to proceed with a minimally invasive laparoscopic or robotic procedure," says Arun Rai, MD, MBA, MSc.
The IND acceptance will initiate the launch of a phase 1 trial to evaluate the safety, tolerability, and preliminary anti-tumor activity of 225Ac-FL-020 in patients with mCRPC.
"This announcement is an important step in increasing the awareness and accessibility of OnQ Prostate beyond its earliest adopters, so that more physicians and patients can benefit from this technology," says Brittany Hunt.
The approval is based on findings from the phase 3 CheckMate-901 study.
Regarding patient-reported outcomes, those who underwent URS showed higher urinary symptoms, greater pain intensity, and greater pain interference at 1 week following surgery compared with those who underwent SWL.
“If approved by the FDA, this new product will have a significant impact on prostate cancer patients, physicians, and their caregivers by helping to eliminate the inequity of access to PSMA-PET agents, and increase the ability to accurately diagnose cancer early, reducing the cost of care, and increasing the probability of patients’ survival," says Mike Crosby.
"In [bladder cancer], many women's diagnosis is delayed because their hematuria or microscopic hematuria is blamed on urinary tract infections rather than cancer," says Amy Luckenbaugh, MD.
"A unique aspect of AUA guidelines is the robust methodological review," says Todd M. Morgan, MD.
Glenn T. Werneburg, MD, PhD, discusses 2 abstracts from the 2024 SUFU Winter Meeting.
The predictive models identified the number of previous UTI episodes, prior β-lactam nonsusceptibility, prior fluoroquinolone treatment, Census Bureau region (particularly in the South), and race as key predictors of having a non-susceptible isolate to 3 or more antibiotic classes.
Raveen Syan, MD, highlights 2 sessions that she took part in during the 2024 AUA Annual Meeting in San Antonio, Texas on urodynamics in the context of the VALUE trial and the new wave of percutaneous tibial nerve stimulation devices.
Some Ascension hospitals continue to divert ambulances to other facilities for emergency treatment, but some of the system’s hospitals are accepting all patients.
Among the 3 CD70-positive patients, the ORR was 66.7%, with 2 patients achieving a partial response.
